Outcomes of PSMA radioligand therapy in lymph node-only metastatic prostate cancer: seven-year results from a single centre
This single-center study of 33 patients with lymph node-only metastatic prostate cancer demonstrates that ¹⁷⁷Lu-PSMA radioligand therapy yields high PSA response rates and favorable survival outcomes with minimal toxicity, particularly in hormone-sensitive and chemotherapy-naïve patients, supporting its earlier introduction in this disease setting.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Prostate cancer is a disease that often begins quietly within the prostate gland, a small organ in men, but it has a habit of spreading to other parts of the body. When it moves, it frequently travels first to the lymph nodes, which are small, bean-shaped structures that act as filters for the immune system. For decades, doctors have viewed the spread of cancer to these nodes as a sign that the disease is no longer curable, usually treating it with hormone therapies that starve the cancer of the signals it needs to grow. However, a newer approach has emerged that targets the cancer cells directly using a tiny, radioactive particle. This treatment, known as radioligand therapy, works like a guided missile: a molecule that seeks out a specific protein found on prostate cancer cells is attached to a radioactive atom. When injected into the body, this combination hunts down the cancer cells and delivers a lethal dose of radiation right where it is needed, sparing most of the healthy tissue around it. While this method has shown promise in patients with widespread disease, it was unclear how well it would work for men whose cancer had spread only to the lymph nodes and nowhere else, a group that often has a better outlook than those with bone metastases.
A team of researchers at a specialized medical center in Australia decided to investigate this specific question by looking back at the records of men they had treated over a seven-year period. They focused on thirty-three patients whose prostate cancer had spread exclusively to lymph nodes, with no evidence of the disease in the bones or internal organs. These men received the targeted radioactive treatment, which was administered intravenously over the course of about ten minutes. The doctors then watched closely to see how the patients responded, tracking changes in a blood marker called PSA, which rises when prostate cancer is active, and monitoring how long the men remained alive without the disease causing their death. The study followed these men for a median of four years, a significant amount of time in the world of cancer research, allowing the team to see not just immediate reactions but also the long-term durability of the treatment.
The results painted a picture of significant success, particularly for men who had not yet received chemotherapy or other aggressive systemic treatments. Among the patients whose cancer was still sensitive to hormone therapy, nearly three-quarters saw their PSA levels drop by at least half, a standard benchmark for a positive response. For those whose cancer had become resistant to hormones but who had never taken chemotherapy, the response was even more striking, with every single patient in that group achieving a fifty percent or greater drop in PSA. Even among the group that had already undergone chemotherapy, nearly half still responded well to the radioactive treatment. The treatment appeared to be remarkably gentle on the body as well; the researchers observed no serious damage to the blood-forming system or the kidneys in the three months following treatment, a finding that contrasts with some other studies involving patients with more extensive disease.
When the researchers looked at how long the men stayed alive without the cancer progressing, the data suggested that the timing of the treatment matters. Men who received the therapy earlier, before their cancer became resistant to hormones or before they had chemotherapy, tended to stay in remission much longer. For the group treated while their cancer was still hormone-sensitive, the median time before the disease progressed was nearly four years, and for some, the cancer had not progressed at all by the end of the study period. In contrast, men who had already received chemotherapy saw their disease return sooner, with a median time to progression of just ten months. Despite these differences in how long the treatment held back the cancer, the overall survival rates were encouraging across the board, with the median time to death from prostate cancer reaching nearly five years for the entire group.
The authors of the study suggest that these findings point toward a potential shift in how doctors might treat prostate cancer that has spread only to the lymph nodes. Because the treatment was effective and well-tolerated, even in men who had not yet tried standard hormone-blocking drugs, it raises the possibility that this targeted radiation could be introduced earlier in the treatment journey, perhaps alongside hormone therapy, rather than waiting until all other options have failed. The researchers acknowledge that their study was a look back at past cases rather than a new experiment, and they note that funding rules in their country meant that many patients had to pay for the treatment themselves, which limited the number of people who could participate. Nevertheless, the data provides a strong signal that for men with lymph-node-only disease, this radioactive approach offers a powerful tool to control the cancer with minimal side effects, offering a new path forward for a group of patients who have traditionally been treated with a one-size-fits-all approach.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.